Business Context and Reporting Period
This Form 8-K Current Report was filed by Lexaria Bioscience Corp. on October 2, 2024, covering events occurring on October 1, 2024. The filing addresses Item 5.02 regarding the appointment of a new Chief Financial Officer (CFO) and the departure of the former CFO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: Michael Shankman was appointed Chief Financial Officer effective October 1, 2024.
- Executive Departure: Nelson Cabatuan resigned as CFO effective July 15, 2024.
- Role Transition: CEO Richard Christopher, who served as interim principal financial and accounting officer, relinquished these duties to Mr. Shankman.
Compensation, Outlook, and Risks
Compensation Arrangements
- Base Salary: Subject to annual increases of 1.25x the annual inflation rate (US Federal Reserve Board).
- Performance Bonuses: Up to 35% of base salary in year one, 40% in year two, and up to 50% thereafter.
- Equity Grant: 50,000 incentive stock options granted on October 1, 2024, with an exercise price of $3.17 per share.
- Vesting Schedule: 20,000 options vest on February 28, 2025; 15,000 on August 31, 2025; and 15,000 on August 31, 2026.
- Severance: Two months' base salary after six months of employment, increasing by one month for each completed year thereafter if terminated without cause.
Risks and Contingencies
The filing notes that the full compensation agreement will be filed as an exhibit to the Annual 10-K report. No specific financial risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the exact base salary amount for Mr. Shankman, which is not disclosed in this filing.
- Review the full employment agreement to be filed as an exhibit to the upcoming 10-K for detailed terms.
- Confirm the current status of the company's cash position given the new executive compensation obligations.
- Monitor the vesting schedule of the 50,000 options granted at $3.17 per share.